title: [Bone marrow graft in hereditary diseases].
abstract: Since 1968, bone marrow transplantation became the first line therapy for selected metabolic and immunological hereditary disorders. Actually, advances in the supportive care in bone marrow transplantation and a better knowledge of the immunology of BMT complications has been associated with a better disease correction and an increase in long term survival. New approaches are under investigation and include: hematopoietic growth factors, enzymatic replacement and gene therapy. However at the present time BMT is still the only curative treatment for selected hereditary disorders.
authors.affiliation: Unité d'Hémato-Oncologie, Hôpital Universitaire des Enfants, Bruxelles.
authors.forename: W
authors.initials: W
authors.lastname: Bujan
authors.forename: A
authors.initials: A
authors.lastname: Ferster
authors.forename: C
authors.initials: C
authors.lastname: Devalck
authors.forename: E
authors.initials: E
authors.lastname: Vamos
authors.forename: F
authors.initials: F
authors.lastname: Mascart
authors.forename: R
authors.initials: R
authors.lastname: Denis
authors.forename: N
authors.initials: N
authors.lastname: Azzi
authors.forename: P
authors.initials: P
authors.lastname: Vergauwen
authors.forename: E
authors.initials: E
authors.lastname: Sariban
mesh_terms: D016026:Bone Marrow Transplantation; D002609:Chediak-Higashi Syndrome / Q000628:therapy; D030342:Genetic Diseases, Inborn / Q000145:classification / Q000628:therapy*; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D008661:Metabolism, Inborn Errors / Q000628:therapy; D014923:Wiskott-Aldrich Syndrome / Q000628:therapy
chemical_list: D006133:Growth Substances
vernacular_title: La greffe de moelle dans les maladies héréditaires.